Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy
Hyun Gul Yang, Moon Cheol Kang, Tae Yoon Kim, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 21

Showing 21 citing articles:

Determinants of response and resistance to CAR T cell therapy
Stefanie Lesch, Mohamed-Reda Benmebarek, Bruno L. Cadilha, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 80-90
Closed Access | Times Cited: 73
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Keerthana Shankar, Christian M. Capitini, Krishanu Saha
Stem Cell Research & Therapy (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 65
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Hamidreza Ebrahimiyan, Amirhossein Tamimi, Bahareh Shokoohian, et al.
International Immunopharmacology (2022) Vol. 106, pp. 108587-108587
Closed Access | Times Cited: 38
Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma
Yalin Tu, Haoran Wu, Chengpeng Zhong, et al.
Gut (2024), pp. gutjnl-332281
Open Access | Times Cited: 7
Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
Lydia T Navarrete-Galvan, Michael Guglielmo, Judith Cruz Amaya, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 28
NKp30 ‐ A prospective target for new cancer immunotherapy strategies
Pedro F. Pinheiro, Gonçalo C. Justino, M. Matilde Marques
British Journal of Pharmacology (2020) Vol. 177, Iss. 20, pp. 4563-4580
Open Access | Times Cited: 39
Shining light on the significance of NK cell CD56 brightness
Sophie M. Poznanski, Ali A. Ashkar
Cellular and Molecular Immunology (2018) Vol. 15, Iss. 12, pp. 1071-1073
Open Access | Times Cited: 33
Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment
Natasha Mupeta Kaweme, Fuling Zhou
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy
Seong Beom An, Bo‐Gie Yang, Gyeonghui Jang, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 18
JEG-3 Trophoblast Cells Influence ILC-like Transformation of NK Cells In Vitro
V. A. Mikhailova, Polina Grebenkina, S. А. Selkov, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 8, pp. 3687-3687
Open Access
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer
Junping Li, Hong Hu, Hui Lian, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1578-1601
Open Access | Times Cited: 3
Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies
Nina B. Horowitz, Imran Mohammad, Uriel Y. Moreno‐Nieves, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 16
Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox
Jiani Xiao, Tianxiang Zhang, Fei Gao, et al.
Cancers (2022) Vol. 14, Iss. 22, pp. 5657-5657
Open Access | Times Cited: 9
A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
Dalai Xu, Yuanqing He, Bin Xiao, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 8
Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells
Elina Parri, Heikki Kuusanmäki, Daria Bulanova, et al.
Blood Advances (2021) Vol. 5, Iss. 7, pp. 1862-1875
Open Access | Times Cited: 8
Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications
Anil Kumar, Sung June Lee, Qiao Liu, et al.
STAR Protocols (2021) Vol. 2, Iss. 4, pp. 100874-100874
Open Access | Times Cited: 6
Fatty acids promote the expansion of NK-92 cells in vitro by improving energy metabolism
Zhepei Xie, Yan Fu, Wen‐Song Tan, et al.
Applied Microbiology and Biotechnology (2021) Vol. 105, Iss. 10, pp. 4285-4295
Closed Access | Times Cited: 5
Gene-Based Natural Killer Cell Therapies for the Treatment of Pediatric Hematologic Malignancies
Ruyan Rahnama, Ilias Christodoulou, Challice L. Bonifant
Hematology/Oncology Clinics of North America (2022) Vol. 36, Iss. 4, pp. 745-768
Open Access | Times Cited: 3
Engineered Natural Killer Cell Lines and Their Application for Cancer Immunotherapy
Ines Kühnel, Torsten Tonn, Winfried S. Wels
Springer eBooks (2024), pp. 1-30
Closed Access
Generation and functional characterization of a multigene-modified NK101 cell line exerting diverse mechanisms of antitumor action
Injung Hwang, Hyun Tak Jin, Moon Cheol Kang, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Optimizing NK-92 Serial Killers: Gamma Irradiation, CD95/FasLigation, And NK Or LAK Attack Limit Cytotoxic Efficacy
Lydia T Navarrete-Galvan, Michael Guglielmo, Judith Cruz Amaya, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 1
Page 1

Scroll to top